FOSL1 promotes tumorigenesis in colorectal carcinoma by mediating the FBXL2/Wnt/β-catenin axis via Smurf1

Yi Liu,Meng Yue,Ze Li
DOI: https://doi.org/10.1016/j.phrs.2020.105405
IF: 10.334
2021-03-01
Pharmacological Research
Abstract:<p>Colorectal carcinoma (CC), one of the most prevalent digestive cancers with high mortality and morbidity globally, still lacks powerful therapies to improve the prognosis. Here, we established that the expression of fos-like antigen-1 (Fosl1) was elevated in CC tissues versus adjacent tissues. Importantly, high Fosl1 expression was related to dismal prognosis among CC patients. Functional assays displayed that Fosl1 increased the viability, epithelial-to-mesenchymal transition (EMT), migration and invasion of CC cells. Additionally, a xenograft assay showed that silencing of Fosl1 in CC cells retarded lung, liver and kidney metastases <em>in vivo</em>. Further investigation demonstrated that Fosl1 was involved in malignant aggressiveness of CC cells by binding to smad ubiquitination regulatory factor 1 (Smurf1). Mechanistically, Smurf1-induced F-Box and leucine rich repeat protein 2 (FBXL2) ubiquitination resulted in its degradation, while FBXL2 disrupted the activation of the Wnt/β-catenin signaling. In summary, Fosl1 plays a pro-metastatic and carcinogenetic role in CC, and we provided forceful evidence that Fosl1 inhibition might act as a prognostic and therapeutic option in CC.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?
The problem this paper attempts to address is the expression of Fosl1 in Colorectal Carcinoma (CC) and its impact on tumorigenesis and metastasis. Specifically, researchers found that the expression of Fosl1 in colorectal carcinoma tissues is significantly higher than in adjacent normal tissues, and high expression of Fosl1 is associated with poor prognosis in patients. Additionally, Fosl1 promotes the proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion capabilities of colorectal carcinoma cells by mediating the Smurf1/FBXL2/Wnt/β-catenin signaling axis, thereby promoting tumorigenesis and development. To verify this hypothesis, researchers conducted the following experiments: 1. **Clinical Sample Analysis**: Detected the expression levels of Fosl1 in tissues from 46 colorectal carcinoma patients and analyzed its relationship with clinicopathological characteristics. 2. **In Vitro Experiments**: Observed the effects of overexpressing or knocking down Fosl1 on the proliferation, EMT, migration, and invasion capabilities of colorectal carcinoma cells. 3. **In Vivo Experiments**: Established an AOM/DSS-induced mouse model of colorectal carcinoma and observed the effects of injecting viral vectors overexpressing or knocking down Fosl1 on tumorigenesis and metastasis. 4. **Molecular Mechanism Study**: Investigated the specific mechanisms by which Fosl1 regulates the malignant behavior of colorectal carcinoma cells through the Smurf1/FBXL2/Wnt/β-catenin signaling axis. Through these experiments, the researchers aim to provide strong evidence for the role of Fosl1 in colorectal carcinoma and explore its potential as a prognostic and therapeutic target for colorectal carcinoma.